Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$179.23
+1.4%
$191.62
$139.41
▼
$216.90
$50.03B0.492.57 million shs682,523 shs
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$802.16
-5.4%
$909.12
$754.00
▼
$1,153.99
$231.43B1.292.21 million shs1.58 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$200.24
+0.5%
$206.87
$22.28
▼
$280.80
$81.01B1.1612.45 million shs4.05 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
+1.41%-2.98%-12.67%-16.11%+18.88%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
-2.88%-7.27%-4.15%-18.60%+7.93%
Moderna, Inc. stock logo
MRNA
Moderna
+1.29%-13.84%-17.66%+37.40%+724.36%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$179.23
+1.4%
$191.62
$139.41
▼
$216.90
$50.03B0.492.57 million shs682,523 shs
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$802.16
-5.4%
$909.12
$754.00
▼
$1,153.99
$231.43B1.292.21 million shs1.58 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$200.24
+0.5%
$206.87
$22.28
▼
$280.80
$81.01B1.1612.45 million shs4.05 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
+1.41%-2.98%-12.67%-16.11%+18.88%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
-2.88%-7.27%-4.15%-18.60%+7.93%
Moderna, Inc. stock logo
MRNA
Moderna
+1.29%-13.84%-17.66%+37.40%+724.36%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
2.94
Moderate Buy$227.3928.64% Upside
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
2.42
Hold$1,052.0424.11% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$120.25-39.67% Downside

Current Analyst Ratings Breakdown

Latest FANG, GS, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Set Price TargetOutperform$240.00
11/17/2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Reiterated RatingMarket Perform$192.00
11/17/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetUnderweight$77.00 ➝ $102.00
11/17/2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Set Price Target$248.00
11/17/2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Boost Price TargetBuy$232.00 ➝ $242.00
11/17/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetEqual Weight$95.00 ➝ $200.00
11/13/2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Boost Price TargetOverweight$221.00 ➝ $223.00
11/11/2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
DowngradeOutperform ➝ Market Perform$221.00 ➝ $192.00
11/11/2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Boost Price TargetBuy$260.00 ➝ $263.00
11/9/2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
DowngradeHold (C+) ➝ Hold (C)
11/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingOverweight$230.00 ➝ $305.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$15.03B3.28$31.57 per share5.60$161.67 per share1.09
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$125.10B1.95$62.65 per share13.53$381.89 per share2.22
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B41.49N/AN/A$16.90 per share11.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$1.66B$7.3124.188.03N/A11.03%11.86%7.31%N/A
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$17.18B$69.5512.1911.470.8215.77%20.21%1.08%1/19/2027 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.10N/AN/AN/A-110.46%-25.79%-15.85%N/A

Latest FANG, GS, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2026Q3 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$1.10$0.38+$1.48$0.38$890.25 million$1.31 billion
11/2/2026Q3 2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$5.72$5.86+$0.14$5.69$4.60 billion$5.43 billion
10/13/2026Q3 2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$12.86$17.01+$4.15$17.01$16.83 billion$18.68 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$4.722.67%+21.67%64.57%7 Years
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$20.002.36%+22.87%28.76%13 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest FANG, GS, and MRNA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/12/2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
quarterly$5.002.24%12/2/202612/2/202612/30/2026
10/29/2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
quarterly$1.182.59%11/12/202611/12/202611/19/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
0.26
0.55
0.54
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
3.20
0.61
0.61
Moderna, Inc. stock logo
MRNA
Moderna
0.52
3.62
3.47

Institutional Ownership

CompanyInstitutional Ownership
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
90.01%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
71.21%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
0.64%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
0.55%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
1,762279.17 million277.38 millionOptionable
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
47,400288.43 million286.85 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700404.62 million360.92 millionOptionable

Recent News About These Companies

Moderna (NASDAQ:MRNA) Stock: Insider Stephen Hoge Sells 39,160 Shares
Bireme Capital Sold Moderna (MRNA) Following Record Rally
Moderna: Can the Vaccine Business Fund Its Next Phase of Growth?
Bireme Capital Sold Moderna (MRNA) Following Record Rally
Moderna (NASDAQ:MRNA) President Sells $8,298,286.15 in Stock
Best Biotech Stocks To Consider - November 18th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Diamondback Energy stock logo

Diamondback Energy NASDAQ:FANG

$179.23 +2.46 (+1.39%)
As of 11:45 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Diamondback Energy, Inc., an independent oil and natural gas company, acquires, develops, explores, and exploits unconventional, onshore oil and natural gas reserves in the Permian Basin in West Texas. It focuses on the development of the Spraberry and Wolfcamp formations of the Midland basin; and the Wolfcamp and Bone Spring formations of the Delaware basin, which are part of the Permian Basin in West Texas and New Mexico. The company also owns and operates midstream infrastructure assets, in the Midland and Delaware Basins of the Permian Basin. Diamondback Energy, Inc. was founded in 2007 and is headquartered in Midland, Texas.

The Goldman Sachs Group stock logo

The Goldman Sachs Group NYSE:GS

$802.16 -45.37 (-5.35%)
As of 11:45 AM Eastern
This is a fair market value price provided by Massive. Learn more.

The Goldman Sachs Group, Inc., a financial institution, provides a range of financial services for corporations, financial institutions, governments, and individuals worldwide. It operates through Global Banking & Markets, Asset & Wealth Management, and Platform Solutions segments. The Global Banking & Markets segment provides financial advisory services, including strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, and spin-offs; and relationship lending, and acquisition financing, as well as secured lending, through structured credit and asset-backed lending and involved in financing under securities to resale agreements. This segment also offers client execution activities for cash and derivative instruments; credit and interest rate products; and provision of mortgages, currencies, commodities, and equities related products, as well as underwriting services. The Asset & Wealth Management segment manages assets across various classes, including equity, fixed income, hedge funds, credit funds, private equity, real estate, currencies, and commodities; and provides customized investment advisory solutions, wealth advisory services, personalized financial planning, and private banking services, as well as invests in corporate equity, credit, real estate, and infrastructure assets. The Platform Solutions segment offers credit cards and point-of-sale financing for purchase of goods or services. This segment also provides cash management services, such as deposit-taking and payment solutions for corporate and institutional clients. The Goldman Sachs Group, Inc. was founded in 1869 and is headquartered in New York, New York.

Moderna stock logo

Moderna NASDAQ:MRNA

$200.24 +0.91 (+0.46%)
As of 11:45 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.